mNSCLC Updates: 1L EGFRm, 2/3L EGFRm & Anti-Trop2 ADC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

OncoAlert

The OncoAlert Colloquium 2022 held in partnership with:
- The American Society for Radiation Oncology
- The European Cancer Organisation
- The European Society for gynaecological oncology
- The European Oncology Nursing society
- The European School of Oncology
- eCancer
- The International Society of Geriatric Oncology
- The ...
read more ↘ multinational Association of Supportive care in cancer
- The SWOG cancer research network

An end of the year review of the best in Oncology 2022, from trials, publications, Drug approvals to current controversies within our field and future trends in treatment and research.

This Colloquium is independent of any financial support and comes to you as the result of our partners and our faculty wanting to drive the field forward worldwide, regardless of geography.

All of the presenters have added their twitter account to the bottom of their presentations in order to facilitate networking, contact and education.

For more information about The OncoAlert Network please visit our website at www.OncoAlert360.com
↖ read less

The 2023 OncoAlert Colloquium
Multidisciplinary Perspectives in Breast Cancer
Florence Breast 2023
ASCO® Highlights
The 2022 OncoAlert Colloquium

Playback speed

10 seconds

mNSCLC Updates: 1L EGFRm, 2/3L EGFRm & Anti-Trop2 ADC

By OncoAlert FEATURING Charu Aggarwal

334 views

February 15, 2024

Disclaimer: On February 16, 2024, the FDA approved osimertinib (TAGRISSO®) with platinum-based chemotherapy for patients with la/mNSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

0 Comments

The 2023 OncoAlert Colloquium